期刊
FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.682492
关键词
cancer; telomerase; immunotherapy; cancer vaccine; hTERT; melanoma; immune response; immuno-oncology
类别
资金
- Norwegian Research Councils [298864]
- Ultimovacs ASA fund
- University of Oslo
Telomerase-based therapeutic cancer vaccines have shown potential in clinical research and may enhance the efficacy of checkpoint inhibition. With its almost universal presence in cancer and essential role in tumor growth, telomerase is an attractive therapeutic target. Rational treatment combinations, such as checkpoint inhibitors, are likely necessary to fully unlock the clinical potential of telomerase-based cancer vaccines.
Telomerase-based therapeutic cancer vaccines (TCVs) have been under clinical investigation for the past two decades. Despite past failures, TCVs have gained renewed enthusiasm for their potential to improve the efficacy of checkpoint inhibition. Telomerase stands as an attractive target for TCVs due to its almost universal presence in cancer and its essential function promoting tumor growth. Herein, we review tumor telomerase biology that may affect the efficacy of therapeutic vaccination and provide insights on optimal vaccine design and treatment combinations. Tumor types possessing mechanisms of increased telomerase expression combined with an immune permissive tumor microenvironment are expected to increase the therapeutic potential of telomerase-targeting cancer vaccines. Regardless, rational treatment combinations, such as checkpoint inhibitors, are likely necessary to bring out the true clinical potential of TCVs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据